Paclitaxel loaded folic acid targeted nanoparticles of mixed lipid-shell and polymer-core: In vitro and in vivo evaluation

Zhao, Peiqi; Wang, Hanjie; Yu, Man; Liao, Zhenyu; Li, Linyu; Zhang, Fei; Ji, Wei; Wu, Bing; Han, Jinghua; Zhang, Haichang; Wang, Huaqing; Chang, Jin; Niu, Ruifang

doi:10.1016/j.ejpb.2012.03.004

Cited by 131 publications

(77 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, using nanocarriers with a high MTD to deliver PTX may permit the administration of Taxol at high doses for preclinical and/or clinical use as an anticancer agent. 7 For these reasons, new formulations such as liposomes, nanoparticles, lipid nanoparticles, and polymeric micelles have been investigated to enhance the targeted delivery of PTX; 6,[8][9][10] however, most of the formulations have not been used clinically. Among these, Abraxane ® is a successful commercial formulation.…”

Section: Introductionmentioning

confidence: 99%

Paclitaxel-loaded hyaluronan solid nanoemulsions for enhanced treatment efficacy in ovarian cancer

Kim¹,

Park²

2017

IJN

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Paclitaxel-loaded hyaluronan solid nanoemulsions for enhanced treatment efficacy in ovarian cancer

Kim¹,

Park²

2017

IJN

View full text Add to dashboard Cite

“…All the formulations, prepared as per the experimental design, exhibited nanoparticle size, ranging between 180 and 280 nm, which is considered ideal for a low emulsification time and enhanced micellar absorption (Zhao et al, 2012). …”

Section: Discussionmentioning

confidence: 99%

Pharmacokinetics andin vivobiodistribution of optimized PLGA nanoparticulate drug delivery system for controlled release of emtricitabine

Singh

Pai

2013

Drug Delivery

View full text Add to dashboard Cite

The objective of this study was to develop systematically optimized (OPT) nanoparticles (NPs) providing a controlled release using PLGA of emtricitabine (FTC) employing Formulation by Design (FbD), and evaluate their in vitro and in vivo performance. FTC generates severe adverse effects with risks of toxicity. Thus, NPs were prepared to reduce these drawbacks in this study. The NPs were prepared by water-in-oil-in-water (w/o/w) emulsion method, followed by high-pressure homogenization. The FTC NPs were systematically OPT using 3 2 central composite design and the OPT formulation located using overlay plot. The pharmacokinetics and in vivo biodistribution of OPT-FTC NPs were investigated in male Wistar rats via the oral administration. Transmission electron microscopy studies on OPT-FTC NPs demonstrated uniform shape and size of particles. In vitro release was sustained up to 15 days in PBS pH 7.4. Augmentation in the values of C max (1.63 fold) and AUC 0-1 (5.39 fold) indicated significant enhancement in the rate and extent of bioavailability by the OPT-FTC NPs compared to pure drug. OPT-FTC NPs showed 2.325 fold increase in the values of FTC concentrations in liver. The OPT-FTC NPs was found to be quite stable during 6 months of study period. Hence, the developed OPT-FTC NPs can be used as drug carrier for sustained/prolonged drug release and/or to reduce toxic effects.

show abstract

“…86,87 Zhao et al used PEGylated octadecyl-quaternized lysine-modified chitosan as a lipid shell for PLGA nanoparticles containing paclitaxel. 88 The surface of the nanoparticles was further functionalized by the conjugation with folic acid for targeted delivery of paclitaxel. In a study of mice bearing cervix tumors, the functional PLGA nanoparticles provided better antitumor efficacy than Taxol.…”

Section: Core-shell Type Hybrid Nanoparticlesmentioning

confidence: 99%

Concepts and practices used to develop functional PLGA-based nanoparticulate systems

Sah¹,

Thoma²,

Desu³

et al. 2013

IJN

198

127

View full text Add to dashboard Cite

Abstract:The functionality of bare polylactide-co-glycolide (PLGA) nanoparticles is limited to drug depot or drug solubilization in their hard cores. They have inherent weaknesses as a drug-delivery system. For instance, when administered intravenously, the nanoparticles undergo rapid clearance from systemic circulation before reaching the site of action. Furthermore, plain PLGA nanoparticles cannot distinguish between different cell types. Recent research shows that surface functionalization of nanoparticles and development of new nanoparticulate dosage forms help overcome these delivery challenges and improve in vivo performance. Immense research efforts have propelled the development of diverse functional PLGA-based nanoparticulate delivery systems. Representative examples include PEGylated micelles/nanoparticles (PEG, polyethylene glycol), polyplexes, polymersomes, core-shelltype lipid-PLGA hybrids, cell-PLGA hybrids, receptor-specific ligand-PLGA conjugates, and theranostics. Each PLGA-based nanoparticulate dosage form has specific features that distinguish it from other nanoparticulate systems. This review focuses on fundamental concepts and practices that are used in the development of various functional nanoparticulate dosage forms. We describe how the attributes of these functional nanoparticulate forms might contribute to achievement of desired therapeutic effects that are not attainable using conventional therapies. Functional PLGA-based nanoparticulate systems are expected to deliver chemotherapeutic, diagnostic, and imaging agents in a highly selective and effective manner.

show abstract

Paclitaxel loaded folic acid targeted nanoparticles of mixed lipid-shell and polymer-core: In vitro and in vivo evaluation

Cited by 131 publications

References 38 publications

Paclitaxel-loaded hyaluronan solid nanoemulsions for enhanced treatment efficacy in ovarian cancer

Paclitaxel-loaded hyaluronan solid nanoemulsions for enhanced treatment efficacy in ovarian cancer

Pharmacokinetics andin vivobiodistribution of optimized PLGA nanoparticulate drug delivery system for controlled release of emtricitabine

Concepts and practices used to develop functional PLGA-based nanoparticulate systems

Contact Info

Product

Resources

About